Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
05:32pm, Tuesday, 03'rd Mar 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
09:00am, Friday, 27'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne
Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP
03:29am, Friday, 27'th Feb 2026
AXQ Capital LP decreased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 72.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities an
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
11:32am, Thursday, 26'th Feb 2026
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
10:31am, Thursday, 26'th Feb 2026
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare w
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinic
Sarepta CEO To Jump Ship After 'Tumultuous' Year
05:52am, Thursday, 26'th Feb 2026
On Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million
Sarepta Therapeutics CEO Ingram to retire by year end
05:05am, Thursday, 26'th Feb 2026
Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
08:27pm, Wednesday, 25'th Feb 2026
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 25'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
09:07am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene mo
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
08:30am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Joel Greenblatt's Strategic Moves: A Closer Look at State Street SPDR S&P 500 ETF Trust
02:01pm, Wednesday, 18'th Feb 2026
Insights from the Fourth Quarter 2025 13F Filing Joel Greenblatt (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providin
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Wednesday, 18'th Feb 2026
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
